Strategic partnerships Pharmaron Radiolabelled Sciences is actively expanding through high-profile collaborations, including a decade-long partnership with Eli Lilly and a strategic CN Bio alliance focused on organ-on-a-chip technologies, signaling ongoing opportunities for co-development and supply arrangements in advanced drug discovery and manufacturing.

Global expansion With operations in China, the US and the UK and recent investments in mRNA and viral vector manufacturing capacity, there is a clear trajectory toward global platform scaling that could align with pharma partners seeking scalable CDMO services, regional manufacturing, and cross-border regulatory support.

Specialized capabilities Pharmaron offers a broad suite of R&D services including radiochemistry, isotopically labelled metabolism, 14C microtracer AMS, gene therapy and CGT facilities, and mRNA/vaccine production capabilities, presenting multiple entry points for customers needing integrated, end-to-end development and regulatory-compliant manufacturing.

Financial signals Revenue is in the small-to-mid millions range for Pharmaron Radiolabelled Sciences, indicating potential for growth within a larger parent platform; sales teams could target tiered collaborations, incremental projects, and scaled services as clients increase their development budgets.

Key personnel and exits Notable leadership movements and a history of senior exits, such as the head of U.S. cell and gene therapy business development transitions, highlight potential for competitive repositioning and the need for outreach strategies that address continuity, relationship mapping, and leverage of ongoing partnerships to win new programs.